Atox Bio Adds $3.25M
Atox Bio, an Israeli pharmaceutical developer, has closed on $3.25 million in financing. Esperante co-led the round with an undisclosed U.S.-based investor. The funds will be used for continued development of its treatment of necrotizing soft tissue infections.
19 December 2011•2 mins read
